OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in CSU Patients

Trial Profile

OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in CSU Patients

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Sep 2017

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Urticaria
  • Focus Registrational; Therapeutic Use
  • Acronyms OPTIMA
  • Sponsors Novartis
  • Most Recent Events

    • 16 Sep 2017 Results presented in a Novartis media release.
    • 16 Sep 2017 According to a Novartis media release, data were presented at the 26th European Academy of Dermatology and Venereology (EADV) Congress.
    • 27 Nov 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top